Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Merck Tagged With Non-compliance In Japan For 3,600 Physicians' Unjustified Honoraria

This article was originally published in PharmAsia News

Executive Summary

TOKYO - Merck & Co. Inc - known as MSD in Japan - is trying to remediate internal oversight measurers quickly after it received a "strict warning" from an independent compliance council for improper payments to a total of 3,604 physicians in Japan between January 2009 and December 2010, which constituted violations of the Fair Competition Code

You may also be interested in...

Merck Looks To Leverage "Next 10" For Growth: Emerging Markets Earnings Roundup (Part 4)

Emerging markets remained a key focus of Big Pharma during first quarter earnings calls. Merck & Co., which aims to see one-fourth of its revenue come from emerging markets by 2013, focused investment in best growth drivers and sales efficiency to bolster key products. Merck's emerging markets strategy will focus on maximizing its own brands, leveraging partnerships with low-cost makers and looking for "inter-brand" opportunities.

Japanese Pharma To Beef Up Transparency Policies In 2011 To Counter Public Concern - APEC Regulatory Conference

SEOUL - Japanese pharma agreed to rollout updated in-house transparency guidelines in 2011 to strengthen compliance and improve the industry's public reputation

GSK Diversification Pays Off With 21% Growth In Asia Pacific Sales: Emerging Markets Earnings Round Up (Part 1)

GlaxoSmithKline PLC April 27 released its first quarter results showing a handsome payoff for a diversification policy the pharmaceutical giant implemented three years ago. Although GSK overall sales declined 11%, strong growth in emerging markets and Japan helped offset losses from key products and bolster the net profit up by 14%.

Related Content

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts